Debt-free Balance SheetA zero-debt capital structure materially lowers bankruptcy and interest-rate risk, preserving strategic optionality. Over 2–6 months this supports funding flexibility for R&D, licensing or pivot initiatives without immediate refinancing pressure, improving resilience.

Improved 2024 ProfitabilityRecording positive EBIT and net income in 2024 indicates management can cut costs or realign operations to profitability. If sustained alongside a revived revenue base, this structural improvement increases the likelihood of self-funded operations and stronger partner outcomes.

Lean Operating FootprintA small workforce implies a lower fixed-cost base, which durablely reduces cash burn while the business repositions. Over months this makes runway extension via cost control more feasible and enables nimble redeployment of resources toward higher-return projects or partnerships.

Bears Say

Revenue Fell To Zero In 2024A complete loss of reported revenue is a structural business-model failure: without sustainable sales or recurring income, profitability and cash metrics are fragile. Over 2–6 months, absent new commercial traction this undermines credibility with partners and access to non-dilutive funding.

Negative Free Cash Flow TrendPersistent negative operating and free cash flow indicates structural cash burn despite accounting profits in 2024. Over the medium term this forces reliance on external financing or asset sales, constraining strategic investments and increasing dilution or refinancing risk.

Compressed Equity And Asset BaseShrinking assets and equity materially reduce balance-sheet firepower for R&D, licensing, or commercialization. Over several months this lowers collateral for lenders, limits ability to absorb shocks, and narrows strategic options like partnerships or acquisitions that require capital backing.

Evolva Holding News

EvoNext Holdings Reports 2025 Half-Year Financials and Strategic M&A Plans

Evolva Holding ( ($CH:EVE) ) just unveiled an update. EvoNext Holdings SA, formerly Evolva Holding SA, has released...

6M ago

Evolva Holding SA Rebrands to EvoNext Holdings SA

The latest announcement is out from Evolva Holding ( ($CH:EVE) ). Evolva Holding SA, a company listed on...

7M ago

EVE FAQ

What was Evolva Holding’s price range in the past 12 months?

Evolva Holding lowest stock price was CHF0.75 and its highest was CHF1.45 in the past 12 months.

What is Evolva Holding’s market cap?

Evolva Holding’s market cap is CHF6.13M.

When is Evolva Holding’s upcoming earnings report date?

Evolva Holding’s upcoming earnings report date is Feb 20, 2026 which is in 3 days.

How were Evolva Holding’s earnings last quarter?

Evolva Holding released its earnings results on Aug 21, 2025. The company reported -CHF0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.05.

Is Evolva Holding overvalued?

According to Wall Street analysts Evolva Holding’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Evolva Holding pay dividends?

Evolva Holding does not currently pay dividends.

What is Evolva Holding’s EPS estimate?

Evolva Holding’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Evolva Holding have?

Evolva Holding has 7,230,626 shares outstanding.

What happened to Evolva Holding’s price movement after its last earnings report?

Evolva Holding reported an EPS of -CHF0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.455%.

Which hedge fund is a major shareholder of Evolva Holding?

Currently, no hedge funds are holding shares in CH:EVE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Evolva Holding

Evolva Holding (EVE) is a Swiss-based biotechnology company focused on the research, development, and commercialization of innovative ingredients derived from nature. The company leverages advanced biosynthesis technology to produce high-value compounds for use in various sectors, including food, cosmetics, and personal care. Evolva's core products are sustainable and environmentally friendly alternatives to traditional ingredients, offering enhanced performance and value.